Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000206070 | SCV000259703 | likely benign | Neurofibromatosis, type 1 | 2024-10-05 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002317732 | SCV000670582 | uncertain significance | Hereditary cancer-predisposing syndrome; Cardiovascular phenotype | 2021-09-16 | criteria provided, single submitter | clinical testing | The p.P6L variant (also known as c.17C>T), located in coding exon 1 of the NF1 gene, results from a C to T substitution at nucleotide position 17. The proline at codon 6 is replaced by leucine, an amino acid with similar properties. This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Genome- |
RCV000206070 | SCV002561389 | uncertain significance | Neurofibromatosis, type 1 | 2022-03-15 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002494520 | SCV002799704 | uncertain significance | Neurofibromatosis, familial spinal; Juvenile myelomonocytic leukemia; Neurofibromatosis, type 1; Neurofibromatosis-Noonan syndrome; Café-au-lait macules with pulmonary stenosis | 2022-03-24 | criteria provided, single submitter | clinical testing |